Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms’ Tumor Suppressor Wt1
Angiogenesis is one hallmark of cancer. Vascular endothelial growth factor (VEGF) is a known inducer of angiogenesis. Many patients benefit from antiangiogenic therapies, which however have limitations. Although VEGF is overexpressed in most tumors, different VEGF isoforms with distinct angiogenic p...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-01-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2073-4409/8/1/41 |
| _version_ | 1797719001244106752 |
|---|---|
| author | Kay-Dietrich Wagner Mounir El Maï Michael Ladomery Tareg Belali Nathalie Leccia Jean-François Michiels Nicole Wagner |
| author_facet | Kay-Dietrich Wagner Mounir El Maï Michael Ladomery Tareg Belali Nathalie Leccia Jean-François Michiels Nicole Wagner |
| author_sort | Kay-Dietrich Wagner |
| collection | DOAJ |
| description | Angiogenesis is one hallmark of cancer. Vascular endothelial growth factor (VEGF) is a known inducer of angiogenesis. Many patients benefit from antiangiogenic therapies, which however have limitations. Although VEGF is overexpressed in most tumors, different VEGF isoforms with distinct angiogenic properties are produced through alternative splicing. In podocytes, the Wilms’ tumor suppressor 1 (WT1) suppresses the Serine/arginine-rich protein-specific splicing factor kinase (SRPK1), and indirectly Serine/arginine-rich splicing factor 1 (Srsf1) activity, and alters VEGF splicing. We analyzed VEGF isoforms, Wt1, Srpk1, and Srsf1 in normal and tumor endothelium. Wt1, Srpk1, Srsf1, and the angiogenic VEGF164a isoform were highly expressed in tumor endothelium compared to normal lung endothelium. Nuclear expression of Srsf1 was detectable in the endothelium of various tumor types, but not in healthy tissues. Inducible conditional vessel-specific knockout of Wt1 reduced Wt1, Srpk1, and Srsf1 expression in endothelial cells and induced a shift towards the antiangiogenic VEGF120 isoform. Wt1(−KTS) directly binds and activates both the promoters of Srpk1 and Srsf1 in endothelial cells. In conclusion, Wt1 activates Srpk1 and Srsf1 and induces expression of angiogenic VEGF isoforms in tumor endothelium. |
| first_indexed | 2024-03-12T08:58:27Z |
| format | Article |
| id | doaj.art-155502f1fcf7492bb9184896f92bb159 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-12T08:58:27Z |
| publishDate | 2019-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-155502f1fcf7492bb9184896f92bb1592023-09-02T15:48:21ZengMDPI AGCells2073-44092019-01-01814110.3390/cells8010041cells8010041Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms’ Tumor Suppressor Wt1Kay-Dietrich Wagner0Mounir El Maï1Michael Ladomery2Tareg Belali3Nathalie Leccia4Jean-François Michiels5Nicole Wagner6Université Côte d’Azur, Institute of Biology Valrose, Nice (iBV), CNRS UMR7277, INSERM U1091, 06107 Nice, FranceUniversité Côte d’Azur, Institute for Research on Cancer and Aging, Nice (IRCAN), CNRS UMR7284/INSERM U1081, 06107 Nice, FranceFaculty of Health and Applied Sciences, University of the West of England, Bristol BS16 1QY, UKFaculty of Health and Applied Sciences, University of the West of England, Bristol BS16 1QY, UKDepartment of Pathology, CHU Nice, 06107 Nice, FranceDepartment of Pathology, CHU Nice, 06107 Nice, FranceUniversité Côte d’Azur, Institute of Biology Valrose, Nice (iBV), CNRS UMR7277, INSERM U1091, 06107 Nice, FranceAngiogenesis is one hallmark of cancer. Vascular endothelial growth factor (VEGF) is a known inducer of angiogenesis. Many patients benefit from antiangiogenic therapies, which however have limitations. Although VEGF is overexpressed in most tumors, different VEGF isoforms with distinct angiogenic properties are produced through alternative splicing. In podocytes, the Wilms’ tumor suppressor 1 (WT1) suppresses the Serine/arginine-rich protein-specific splicing factor kinase (SRPK1), and indirectly Serine/arginine-rich splicing factor 1 (Srsf1) activity, and alters VEGF splicing. We analyzed VEGF isoforms, Wt1, Srpk1, and Srsf1 in normal and tumor endothelium. Wt1, Srpk1, Srsf1, and the angiogenic VEGF164a isoform were highly expressed in tumor endothelium compared to normal lung endothelium. Nuclear expression of Srsf1 was detectable in the endothelium of various tumor types, but not in healthy tissues. Inducible conditional vessel-specific knockout of Wt1 reduced Wt1, Srpk1, and Srsf1 expression in endothelial cells and induced a shift towards the antiangiogenic VEGF120 isoform. Wt1(−KTS) directly binds and activates both the promoters of Srpk1 and Srsf1 in endothelial cells. In conclusion, Wt1 activates Srpk1 and Srsf1 and induces expression of angiogenic VEGF isoforms in tumor endothelium.http://www.mdpi.com/2073-4409/8/1/41VEGF isoformssplicing factorsendotheliumtranscriptional regulationWilms’ tumor suppressor Wt1 |
| spellingShingle | Kay-Dietrich Wagner Mounir El Maï Michael Ladomery Tareg Belali Nathalie Leccia Jean-François Michiels Nicole Wagner Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms’ Tumor Suppressor Wt1 Cells VEGF isoforms splicing factors endothelium transcriptional regulation Wilms’ tumor suppressor Wt1 |
| title | Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms’ Tumor Suppressor Wt1 |
| title_full | Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms’ Tumor Suppressor Wt1 |
| title_fullStr | Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms’ Tumor Suppressor Wt1 |
| title_full_unstemmed | Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms’ Tumor Suppressor Wt1 |
| title_short | Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms’ Tumor Suppressor Wt1 |
| title_sort | altered vegf splicing isoform balance in tumor endothelium involves activation of splicing factors srpk1 and srsf1 by the wilms tumor suppressor wt1 |
| topic | VEGF isoforms splicing factors endothelium transcriptional regulation Wilms’ tumor suppressor Wt1 |
| url | http://www.mdpi.com/2073-4409/8/1/41 |
| work_keys_str_mv | AT kaydietrichwagner alteredvegfsplicingisoformbalanceintumorendotheliuminvolvesactivationofsplicingfactorssrpk1andsrsf1bythewilmstumorsuppressorwt1 AT mounirelmai alteredvegfsplicingisoformbalanceintumorendotheliuminvolvesactivationofsplicingfactorssrpk1andsrsf1bythewilmstumorsuppressorwt1 AT michaelladomery alteredvegfsplicingisoformbalanceintumorendotheliuminvolvesactivationofsplicingfactorssrpk1andsrsf1bythewilmstumorsuppressorwt1 AT taregbelali alteredvegfsplicingisoformbalanceintumorendotheliuminvolvesactivationofsplicingfactorssrpk1andsrsf1bythewilmstumorsuppressorwt1 AT nathalieleccia alteredvegfsplicingisoformbalanceintumorendotheliuminvolvesactivationofsplicingfactorssrpk1andsrsf1bythewilmstumorsuppressorwt1 AT jeanfrancoismichiels alteredvegfsplicingisoformbalanceintumorendotheliuminvolvesactivationofsplicingfactorssrpk1andsrsf1bythewilmstumorsuppressorwt1 AT nicolewagner alteredvegfsplicingisoformbalanceintumorendotheliuminvolvesactivationofsplicingfactorssrpk1andsrsf1bythewilmstumorsuppressorwt1 |